Arkolith/Insider Trading/ACAD/Form 4

Schneyer Mark C.

EVP, CHIEF FINANCIAL OFFICERACADIA PHARMACEUTICALS INC (ACAD) · full profile →Form 4 · filed Mar 26, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$159K
Net Open-Market Flow
-$159K
Transactions
7
5 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 26, 2026Sell(S)37$21.72$80460K
Mar 26, 2026Sell(S)3K$21.65$69K60K
Mar 25, 2026Sell(S)4K$21.47$90K57K
Mar 25, 2026Option exercise(M)6K——63K
Mar 24, 2026Option exercise(M)8K——61K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 25, 2026Option exercise(M)6K—$012K
Mar 24, 2026Option exercise(M)8K—$024K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001899977-26-000003) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML